x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243110
| Product Information | |
|---|---|
| CAS No. | 1245603-92-2 |
| Synonyms | PF-04937319 |
| Formula | C22H20N6O4 |
| Molecular Weight | 432.43 |
| SMILES | O=C(C1=NC=C(OC2=C3C=C(C)OC3=CC(C(NC4=NC=C(C)N=C4)=O)=C2)C=N1)N(C)C |
| Target | Glucokinase |
| Product Description | Nerigliatin (PF-04937319) is a glucokinase activator (GKA) with EC50 value of 154.4 ?μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus. Nerigliatin is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to yellow |
| Purity | 99.78% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 6 months; -20°C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
